Assess whether scientific advice should be sought before the next trial

SITUATION After a literature paper the 505(b)(2) package leans on getting retracted, RWE protocol that may not meet regulator expectations is what regulatory-affairs lead can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this FDA Response and Labeling file.

DECISION Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. RWE protocol that may not meet regulator expectations reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population. 2. RWE protocol that may not meet regulator expectations is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this FDA Response and Labeling extract. 3. Escalate safety review is still live in RWE protocol that may not meet regulator expectations for regulatory-affairs lead in a mid-size sponsor after a complete response letter. 4. RWE protocol that may not meet regulator expectations is missing the fact regulatory-affairs lead needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move scientific advice should be for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted). If RWE protocol that may not meet regulator expectations cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a mid-size sponsor after a complete response letter does not have.